Speakers

Expand/Collapse

Amr Abdeen
Postdoctoral Associate
University of Wisconsin- Madison

Discussion Day

3:00 pm | Improved Non-Viral Vectors for In Vivo Genome Editing

Omar Abudayyeh
McGovern Fellow
Harvard University

Day Two

Thursday May 21 2020

10:31 am | Harnessing Novel CRISPR Tools for Genome Engineering and RNA Editing

Fernando Aleman
Co-Founder & Chief Scientific Officer
Navega Therapeutics

Andrew Anzalone
Head of Prime Editing Platforms
Prime Medicine

Day One

Wednesday May 20 2020

10:00 am | Exploring the Potential of Prime Editing

Luis Barrera
Head of Computational Sciences
Beam Therapeutics

Day Two

Thursday May 21 2020

3:00 pm | Comprehensive Identification of Base Editor Off-Targets in the Context of Therapeutically Relevant Delivery

1:30 pm | Panel Discussion: Do CRISPR Tools Need to be Perfect?

Delai Chen
Associate Director, Nanoparticle Formulation
Beam Therapeutics

Discussion Day

1:15 pm | Panel Discussion: Discussing the Future of CRISPR Delivery: Will One Modality Emerge as Superior?

Paul Diehl
Chief Operating Officer
Cellecta

Day One

Wednesday May 20 2020

1:00 pm | Functional CRISPR Screening and Cell Barcoding to Identify Genes Driving Biological Responses and Disease Progression

Rafi Emmanuel
Research Director
Emendo Biotherapeutics

Day One

Wednesday May 20 2020

4:15 pm | Target Optimized Variant of CRISPR Associated Nuclease Enables Allele-Specific Knock Out of ELANE-Related Neutropenia

Jonathan Gootenberg
McGovern Fellow
Harvard University

Day Two

Thursday May 21 2020

10:30 am | CRISPR Diagnostics: Expanding the Nucleic Acid Detection Toolbox by Harnessing Microbial Diversity

Julian Grunewald
Research Fellow
Joung Lab, Massachusetts General

Day One

Wednesday May 20 2020

10:30 am | Developing and Improving Base Editors

Killian Hanlon
Research Fellow
Harvard University

Discussion Day

11:15 am | Overcoming Limitations of Viral Vectors to Deliver CRISPR Machinery

Ben Kleinstiver
Principal Investigator
Massachusetts General

Day Two

Thursday May 21 2020

1:00 pm | Broadly Useful Engineered CRISPR-Cas Enzymes with Enhanced Properties

Sanne Klompe
Graduate
Sternberg Lab, Columbia University

Day One

Wednesday May 20 2020

12:30 pm | Utilizing CRISPR-Associated Transposons for Programmed Insertions Without Generating Double-Strand Breaks

Kunwoo Lee
Chief Executive Officer & Co-Founder
GenEdit

Discussion Day

1:15 pm | Panel Discussion: Discussing the Future of CRISPR Delivery: Will One Modality Emerge as Superior?

12:45 pm | Non-Viral Delivery of CRISPR Using Polymer Nanoparticles

Blair Madison
Senior Director, Genetic Engineering
Poseida Therapeutics

Day Two

Thursday May 21 2020

3:30 pm | Creating Novel Proteins to Optimize Efficacy and Specificity

1:30 pm | Panel Discussion: Do CRISPR Tools Need to be Perfect?

Peter Marks
Director, CBER
FDA

Day Two

Thursday May 21 2020

9:30 am | FDA’s Regulatory Approach to Applications of CRISPR

Niren Murthy
Professor
University of California at Berkeley

Discussion Day

12:15 pm | Gene Editing After Local Injection: Non-Viral Delivery

Kiran Musunuru
Principal Investigator
University of Pennsylvania

Day Two

Thursday May 21 2020

2:30 pm | Applying CRISPR to Predict and Treat Cardiovascular Disease

Kalina Paunovska
Postdoctoral Fellow
Dahlman Lab, Georgia Tech

Discussion Day

3:30 pm | Delivering CRISPR Apparatus In Vivo Using Nanoparticle Technology

Karl Petri
Research Fellow
Joung Lab, Massachusetts General

Day One

Wednesday May 20 2020

5:15 pm | ONE-seq: Detection of CRISPR Nuclease and Base Editor Off-Targets with Ultra-High Sensitivity to Ensure the Safety of CRISPR Therapeutics

Sicco Popma
Founder, Chief Executive Officer & President
IO Biosciences

Day Two

Thursday May 21 2020

5:00 pm | Developing CRISPR-Based Cell Therapies Using a Proprietary Gene Editing System (GEMS)

Satinder Rawat
Senior Licensing Officer
University of Massachusetts

Day One

Wednesday May 20 2020

3:45 pm | Bridging the Gap Between Academia and Industry: Translating Cutting-Edge Technologies from the Lab to the Clinic

David Schaffer
Co-Founder
4D Molecular Therapeutics

Discussion Day

10:45 am | Directed Evolution of Novel AAV Variants for Clinical Gene Therapy

Brett Staahl
Founder & Head of Applied Technologies
Scribe Therapeutics

Discussion Day

10:15 am | Why Isn’t the Future of Medicine Here Yet?

Marija Tadin- Strapps
Vice President, Exploratory Biology
SQZ Biotechnologies

Discussion Day

4:00 pm | CellSQZ platform for Development of Next Generation Cell Therapies

Fyodor Urnov
Scientific Director
Innovative Genomics Institute

Day One

Wednesday May 20 2020

6:15 pm | Chair’s Closing Remarks

9:30 am | KEYNOTE: CRISPR 2030: the Promise and the Challenge

9:20 am | Chair’s Opening Remarks

Rui Wang
Principal Research Scientist
Abbvie

Renee Wegrzyn
Program Manager
DARPA

Day Two

Thursday May 21 2020

12:30 pm | Programmable Gene Modulation

Carlo Zambonelli
Associate Director
Beam Therapeutics

Day One

Wednesday May 20 2020

5:45 pm | Developing Assays and Tools for Base Editing

Kate Zhang
Vice President, Biological Development
Editas Medicine

Lihua Julie Zhu
Professor & Head of Bioinformatics Core
University of Massachusetts

Speaker to be Confirmed

Aldevron

Day One

Wednesday May 20 2020

3:30 pm | Slot Reserved for Aldevron

Lumeng Ye
Senior Scientist
GenScript Biotech Corp.

Day One

Wednesday May 20 2020

1:20 pm | Precise, Non-Viral, CAR-T Engineering with CRISPR sgRNA and ssDNA